Evidence map›Paper›PMID 34203761›Full record

ArticlePharmaceutics2021

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden.

Sofia Sagredou, Panagiotis Dalezis, Eirini Papadopoulou, Maria Voura, Maria V Deligiorgi, Michail Nikolaou, Mihalis I Panayiotidis, George Nasioulas, Vasiliki Sarli, Dimitrios T Trafalis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Sofia SagredouLaboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece.ORCID 0000-0001-9281-7947
Panagiotis DalezisLaboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece.ORCID 0000-0001-7680-7685
Eirini PapadopoulouGenekor Medical, Spaton 52, Ave., 15344 Athens, Greece.
Maria VouraDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.
Maria V DeligiorgiLaboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece.
Michail NikolaouLaboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece.ORCID 0000-0002-7215-6296
Mihalis I PanayiotidisDepartment of Electron Microscopy & Molecular Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia 2371, Cyprus.ORCID 0000-0002-1450-3552
George NasioulasGenekor Medical, Spaton 52, Ave., 15344 Athens, Greece.
Vasiliki SarliDepartment of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.ORCID 0000-0002-6128-8277
Dimitrios T TrafalisLaboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece.ORCID 0000-0003-4066-9780
National and Kapodistrian University of Athens · GRAristotle University of Thessaloniki · GRAthens Medical Center · GRCyprus Institute of Neurology and Genetics · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microsatellite instability (MSI), tumor mutation burden (TMB), and programmed cell death ligand-1 (PD-L1) are particularly known as immunotherapy predictive biomarkers. MSI and TMB are closely related to DNA mismatch repair (MMR) pathway functionality, while the PD-L1 checkpoint mediates cancer cell evasion from immune surveillance via the PD-L1/PD-1 axis. Among all the novel triazolo[3,4-

Indexed as

cancer immunogenic markersMMR impairmentPD-L1 upregulationthiadiazole derivativetumor mutation burden

Identifiers

PMID34203761
PMCPMC8232699
OpenAlexW3171192523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.